Vivo Capital LLC Acquires Shares of 722,020 Sensei Biotherapeutics, Inc. $FTH

Vivo Capital LLC acquired a new stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 722,020 shares of the company’s stock, valued at approximately $22,758,000. Sensei Biotherapeutics makes up 1.9% of Vivo Capital LLC’s investment portfolio, making the stock its 19th largest holding. Vivo Capital LLC owned approximately 0.54% of Sensei Biotherapeutics at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Renaissance Technologies LLC lifted its position in shares of Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after buying an additional 1,100 shares in the last quarter. Bank of America Corp DE boosted its stake in Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the last quarter. Finally, Stempoint Capital LP purchased a new position in Sensei Biotherapeutics during the 1st quarter valued at approximately $4,188,000. 10.50% of the stock is owned by institutional investors.

Sensei Biotherapeutics Stock Down 0.4%

FTH opened at $28.82 on Friday. The stock has a market capitalization of $38.62 million, a P/E ratio of -0.20 and a beta of -0.26. Sensei Biotherapeutics, Inc. has a 12 month low of $7.10 and a 12 month high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. Analysts anticipate that Sensei Biotherapeutics, Inc. will post -16.61 earnings per share for the current year.

Insider Transactions at Sensei Biotherapeutics

In related news, CEO Anand Kiran Parikh purchased 2,806 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the acquisition, the chief executive officer owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This represents a 0.37% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Brian C. Stephenson purchased 9,391 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was bought at an average price of $26.13 per share, with a total value of $245,386.83. Following the completion of the transaction, the chief financial officer owned 26,804 shares of the company’s stock, valued at $700,388.52. The trade was a 53.93% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 49,494 shares of company stock worth $1,188,822. 7.00% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on FTH shares. Wall Street Zen downgraded Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Citigroup started coverage on Sensei Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $55.00 target price for the company. BTIG Research reissued a “buy” rating and issued a $55.00 target price on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. Oppenheimer initiated coverage on shares of Sensei Biotherapeutics in a research report on Tuesday. They issued an “outperform” rating and a $60.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $54.75.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.